CHRSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Coherus Oncology, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$0.96−0.03 (-3.16%)
Close on Oct 19, 2026
- Market cap
- $148.42M
- P/E (TTM)
- 0.7
- Dividend yield
- –
Coherus Oncology statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Biological Products, (No Diagnostic Substances) companies for comparison
Valuation
| Measure | Coherus Oncology | Industry median |
|---|---|---|
| Market Cap | $148.12M | $164.85M |
| Enterprise Value | $42.82M | $87.06M |
| PS Ratio | 2.91 | 3.60 |
| PB Ratio | 2.43 | 2.03 |
| P/TBV Ratio | 3.52 | 2.31 |
Enterprise value
| Measure | Coherus Oncology | Industry median |
|---|---|---|
| EV / Sales | 0.84 | 2.43 |
Income (trailing twelve months)
| Measure | Coherus Oncology | Industry median |
|---|---|---|
| Revenue | $50.94M | $57.94M |
| Gross Profit | $35.11M | $90.47M |
| Operating Income | -$158.70M | -$21.44M |
| Pretax Income | -$161.15M | -$14.45M |
| Net Income | -$132.13M | -$22.46M |
| EBITDA | -$156.35M | -$16.91M |
Margins
| Measure | Coherus Oncology | Industry median |
|---|---|---|
| Gross Margin | 68.9% | 52.3% |
| Operating Margin | -311.6% | -44.5% |
| Pretax Margin | -316.4% | -13.0% |
| Profit Margin | -259.4% | -39.2% |
| EBITDA Margin | -307.0% | -31.3% |
Returns
| Measure | Coherus Oncology | Industry median |
|---|---|---|
| Return on Equity (ROE) | -146.3% | -53.1% |
| Return on Assets (ROA) | -41.9% | -41.0% |
| Return on Capital Employed (ROCE) | -137.2% | -37.8% |
Growth
| Measure | Coherus Oncology | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 61.0% | 6.01% |
| Net Income Growth (YoY) | -173.5% | -37.7% |
| Revenue Growth (3Y CAGR) | -41.5% | 2.25% |
| Revenue Growth (5Y CAGR) | -38.4% | 6.42% |
| EPS Growth (5Y CAGR) | -2.46% | 3.77% |
Balance sheet
| Measure | Coherus Oncology | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $105.30M | $62.42M |
| Net Cash (Debt) | $105.30M | $15.68M |
| Net Cash Per Share | $0.68 | $0.66 |
| Equity (Book Value) | $60.84M | $48.79M |
| Book Value Per Share | $0.39 | $1.36 |
| Tangible Book Value | $42.09M | $23.06M |
| Working Capital | $58.28M | $75.77M |
Financial position
| Measure | Coherus Oncology | Industry median |
|---|---|---|
| Current Ratio | 1.77 | 3.30 |
| Quick Ratio | 1.58 | 2.39 |
| Interest Coverage | -17.47 | -7.12 |
Cash flow (trailing twelve months)
| Measure | Coherus Oncology | Industry median |
|---|---|---|
| Operating Cash Flow | -$186.03M | -$12.35M |
Efficiency
| Measure | Coherus Oncology | Industry median |
|---|---|---|
| Asset Turnover | 0.16 | 0.38 |
| Inventory Turnover | 3.11 | 2.67 |
| Revenue Per Employee | $346.50K | $398.96K |
| Profits Per Employee | -$898.86K | -$703.34K |
| Employee Count | 147 | 74 |
Dividends and yields
| Measure | Coherus Oncology | Industry median |
|---|---|---|
| Earnings Yield | -89.2% | -22.7% |
Shares
| Measure | Coherus Oncology | Industry median |
|---|---|---|
| Shares Outstanding | 154,501,000 | 58,179,650 |
| Shares Change (YoY) | 14.1% | 11.1% |
| Shares Change (QoQ) | 0.16% | 0.54% |
| Float | 152,507,000 | 49,173,100 |
| Shares Held by Insiders | 1.29% | 11.6% |
| Shares Held by Institutions | 45.5% | 59.4% |
Scores
| Measure | Coherus Oncology | Industry median |
|---|---|---|
| Altman Z-Score | -11.98 | -0.24 |
| Piotroski F-Score | 6 | 4 |
| Beneish M-Score | 2.81 | -2.62 |
Calculated by StockData from Coherus Oncology's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.